Can-Fite BioPharma Ltd. (CANF) Form 6-K — Oct 26, 2026
Can-Fite BioPharma presented final positive data from its Phase IIa pancreatic cancer study of namodenoson at the ESMO 2026 Congress. The 20-patient open-label study achieved its primary safety endpoint, with only five mild-to-moderate treatment-related adverse events and no Grade 3+ or serious treatment-related events. Exploratory analyses showed encouraging survival signals: in eight third-line patients surviving beyond two months, median overall survival was 6.28 months, and one second-line patient achieved progression-free survival of 16.39 months with overall survival exceeding 20.7 months.
Key figures
- Dose
- 25 mg twice daily
- Data Cutoff Date
- September 23, 2026
- Enrolled Patients
- 20
- Outlier Patient OS
- 20.7 months
- Outlier Patient PFS
- 16.39 months
- Treatment Related AEs
- 5 adverse events in 3 patients, all Grade 1-2
- Third Line Subgroup Size
- 8
- Median Overall Survival Third Line
- 6.28 months
- Median Progression Free Survival Third Line
- 2.27 months
- Study design
- single-center, open-label Phase IIa
- Third line patients
- 14
- Fourth line patients
- 3
- Second line patients
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.